Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,150 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Sale · Disposed 6,400 · Balance 48,150 F1: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 6,400 | $2.23 | $14,272.64 |
DisclosureSEC source: 0001628280-26-042280 · wk-form4_1781124671.xml · nonDerivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,150 F1 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 53,250 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001628280-26-041281 · wk-form4_1780691540.xml · derivative · entry 2 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 Underlying: Common Stock · 53,250 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041281 · wk-form4_1780691540.xml · nonDerivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,550 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001576885-25-000080 · wk-form4_1749156801.xml · derivative · entry 2 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000080 · wk-form4_1749156801.xml · nonDerivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,050 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:41 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001576885-24-000077 · wk-form4_1718052104.xml · derivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:42 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001576885-23-000033 · wk-form4_1686174109.xml · derivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:27 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-037889 · doc4.xml · derivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:13 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | PurchaseCommon Stock | 6,250 | $16.00 | $100,000.00 |
DisclosureSEC source: 0001209191-21-046026 · doc4.xml · nonDerivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044947 · doc4.xml · derivative · entry 1 Fountain Nathan B · CIK 0001869596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.